Among LPA receptors, the LPA1-dependent cellular pathway has been particularly well studied for the treatment of fibrosis and LPA1 antagonists have entered phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrogenic conditions [13]. The gene discussed is LPAR1; the disease is fibrosis.